This page contains a Flash digital edition of a book.
academic and clinical focus.

PCBNet: Stem Cells, Prion Proteins and Alzheimer’s Diseases, A Prion Chemical Biology Network

A national Prion Chemical Biology Network has recently been launched. The network provides a forum for researchers from across the UK and Europe to meet, exchange ideas and expertise, and form new partnerships.

PCBNet will help to foster existing and new academic – user collaborations which will allow network members to develop new understanding, ideas and concepts that will contribute towards solving research challenges in the field of prion chemical biology, particularly in relation to age related diseases such as Alzheimer’s disease.

The prion chemical biology network is one of 7 new networks established this year with £1.2 million investment from EPSRC, BBSRC and MRC to aid research and knowledge-sharing at the chemical biology interface.

Our aim is to enable the scientific community to expand its understanding of the role of prions in biology and to accelerate progress to new diagnostic and therapeutic tools for the improvement of human health and to create a lasting interdisciplinary research community.

We will be running a series of network meeting and workshops, visit to find out about upcoming events, more about the network and to join PCBNet.

The Future of Transplantation

An Institute of Transplantation has recently opened at the Freeman Hospital in Newcastle upon Tyne, and is an exciting new site for the development of cellular therapies by clinicians.

The Freeman Hospital is a world-leading centre for all types of organ transplantation, including newer cell-based transplants such as pancreatic islet transplantation, which have been brought together in a purpose built, state of the art building. Research carried out at the Institute will include the use of stem cells to support failing organs, modification of recipient immune response and transplant rejection, and one day providing an alternative to organ transplantation altogether. Clinicians based at the Institute of Transplantation will be working with NESCI scientists to develop these new therapies and progress them quickly into a clinical setting.

For further information: transplantation.aspx

ATMP Trials in Pipeline

The BioManufacturing Facility in Newcastle is on track to gain accreditation for the production of Advanced Therapy Medicinal Products (ATMPs) by the MHRA following an inspection later this summer.

The Facility is split across two sites in Newcastle upon Tyne – at the Centre for Life and the Royal Victoria Infirmary – and is one of the largest clean room facilities dedicated to cell therapy manufacture in Europe. There are three projects waiting to manufacture samples for cell therapy clinical trials upon MHRA authorisation – autologous limbal stem cells for treating limbal stem cell deficiency, allogeneic mesenchymal stem cells for treating graft vs host disease and autologous tolerogenic dendritic cells for treating rheumatoid arthritis.

Anyone interested in learning more about this work or in using the facility should contact


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36